Do analysts rate CPHI or ENSC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to CPHI or ENSC?

In the previous week, China Pharma and China Pharma both had 1 articles in the media. China Pharma's average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ensysce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ABVC or ENSC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ABVC or ENSC?

In the previous week, ABVC BioPharma and ABVC BioPharma both had 1 articles in the media. ABVC BioPharma's average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ensysce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate OPTH or ENSC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer OPTH or ENSC?

In the previous week, Optimi Health had 2 more articles in the media than Ensysce Biosciences. MarketBeat recorded 3 mentions for Optimi Health and 1 mentions for Ensysce Biosciences. Optimi Health's average media sentiment score of 0.99 beat Ensysce Biosciences' score of 0.00 indicating that Optimi Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Optimi Health 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ensysce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ENSC or LONA?

Athira Pharma has a consensus target price of $17.33, suggesting a potential upside of 233.33%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than Ensysce Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to ENSC or LONA?

In the previous week, Athira Pharma had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 2 mentions for Athira Pharma and 1 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.00 equaled Athira Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ensysce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Athira Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer VIRI or ENSC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Ensysce Biosciences (ENSC) Competitors

$0.42 +0.02 (+6.08%)

Closing price 04:00 PM Eastern

Extended Trading

$0.40 -0.02 (-3.58%)

As of 06:47 PM Eastern

Compare

ENSC vs. CPHI, ABVC, OPTH, LONA, and VIRI

Should you buy Ensysce Biosciences stock or one of its competitors? Ensysce Biosciences's main competitors and comparable companies include China Pharma (CPHI), ABVC BioPharma (ABVC), Optimi Health (OPTH), Athira Pharma (LONA), and Virios Therapeutics (VIRI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ensysce Biosciences compare to China Pharma?

China Pharma (NYSE:CPHI) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

5.6% of Ensysce Biosciences shares are owned by institutional investors. 6.4% of China Pharma shares are owned by insiders. Comparatively, 2.8% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, China Pharma and China Pharma both had 1 articles in the media. China Pharma's average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ensysce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

China Pharma has higher earnings, but lower revenue than Ensysce Biosciences. China Pharma is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	7.22	-$3.08M	-$0.43	N/A
Ensysce Biosciences	$5.07M	1.52	-$10.18M	-$2.76	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

China Pharma has a net margin of -85.56% compared to Ensysce Biosciences' net margin of -280.53%. China Pharma's return on equity of -63.93% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%

China Pharma has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.

Summary

China Pharma beats Ensysce Biosciences on 8 of the 12 factors compared between the two stocks.

How does Ensysce Biosciences compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

In the previous week, ABVC BioPharma and ABVC BioPharma both had 1 articles in the media. ABVC BioPharma's average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ensysce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 2.8% of Ensysce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ABVC BioPharma has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. ABVC BioPharma's return on equity of -47.68% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%

ABVC BioPharma has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.

ABVC BioPharma has higher earnings, but lower revenue than Ensysce Biosciences. ABVC BioPharma is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	52.86	-$7.91M	-$0.30	N/A
Ensysce Biosciences	$5.07M	1.52	-$10.18M	-$2.76	N/A

Summary

ABVC BioPharma beats Ensysce Biosciences on 8 of the 11 factors compared between the two stocks.

How does Ensysce Biosciences compare to Optimi Health?

Optimi Health (NASDAQ:OPTH) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Optimi Health has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. Optimi Health's return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Optimi Health	N/A	N/A	N/A
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Optimi Health had 2 more articles in the media than Ensysce Biosciences. MarketBeat recorded 3 mentions for Optimi Health and 1 mentions for Ensysce Biosciences. Optimi Health's average media sentiment score of 0.99 beat Ensysce Biosciences' score of 0.00 indicating that Optimi Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Optimi Health	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ensysce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

5.6% of Ensysce Biosciences shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Optimi Health has higher earnings, but lower revenue than Ensysce Biosciences. Optimi Health is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Optimi Health	$310K	82.99	-$1.12M	-$0.76	N/A
Ensysce Biosciences	$5.07M	1.52	-$10.18M	-$2.76	N/A

Summary

Optimi Health beats Ensysce Biosciences on 9 of the 13 factors compared between the two stocks.

How does Ensysce Biosciences compare to Athira Pharma?

Ensysce Biosciences (NASDAQ:ENSC) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Ensysce Biosciences has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.Comparatively, Athira Pharma has a beta of 2.11, meaning that its share price is 111% more volatile than the broader market.

In the previous week, Athira Pharma had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 2 mentions for Athira Pharma and 1 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.00 equaled Athira Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ensysce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Athira Pharma has a consensus target price of $17.33, suggesting a potential upside of 233.33%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by company insiders. Comparatively, 25.7% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Athira Pharma has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. Athira Pharma's return on equity of -411.58% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%
Athira Pharma	N/A	-411.58%	-225.73%

Ensysce Biosciences has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	1.64	-$10.18M	-$2.76	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A

Summary

Athira Pharma beats Ensysce Biosciences on 10 of the 14 factors compared between the two stocks.

How does Ensysce Biosciences compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

In the previous week, Ensysce Biosciences had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for Ensysce Biosciences and 0 mentions for Virios Therapeutics. Virios Therapeutics' average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Ensysce Biosciences	Neutral

Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Virios Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. Virios Therapeutics' return on equity of -130.33% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Virios Therapeutics has higher earnings, but lower revenue than Ensysce Biosciences. Virios Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Ensysce Biosciences	$5.07M	1.52	-$10.18M	-$2.76	N/A

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Ensysce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Virios Therapeutics beats Ensysce Biosciences on 8 of the 12 factors compared between the two stocks.

Get Ensysce Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENSC vs. The Competition

Export

Metric	Ensysce Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.15M	$12.12B	$7.17B	$13.38B
Dividend Yield	N/A	2.65%	2.53%	17.32%
P/E Ratio	-0.15	799.72	274.64	26.20
Price / Sales	1.61	755.20	608.57	90.53
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	0.67	10.68	11.26	6.40
Net Income	-$10.18M	$2.83B	$3.49B	$381.07M
7 Day Performance	4.46%	-2.20%	-1.68%	-0.65%
1 Month Performance	-8.05%	-6.54%	-5.97%	-4.51%
1 Year Performance	-83.50%	-4.52%	8.11%	1.82%

Ensysce Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENSC Ensysce Biosciences	1.096 of 5 stars	$0.42 +6.1%	N/A	-84.4%	$8.15M	$5.07M	N/A	10
CPHI China Pharma	N/A	$0.66 -8.0%	N/A	-65.2%	$28.31M	$3.91M	N/A	221	Gap Down
ABVC ABVC BioPharma	0.3393 of 5 stars	$1.04 -1.0%	N/A	-66.3%	$27.99M	$510K	N/A	19	News Coverage
OPTH Optimi Health	0.6553 of 5 stars	$4.78 -1.4%	N/A	N/A	$27.77M	$310K	N/A	9
LONA Athira Pharma	2.9886 of 5 stars	$3.51 +22.3%	$17.33 +393.8%	N/A	$26.96M	N/A	N/A	19	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENSC) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ensysce Biosciences (ENSC) Competitors

ENSC vs. CPHI, ABVC, OPTH, LONA, and VIRI

How does Ensysce Biosciences compare to China Pharma?

Summary

How does Ensysce Biosciences compare to ABVC BioPharma?

Summary

How does Ensysce Biosciences compare to Optimi Health?

Summary

How does Ensysce Biosciences compare to Athira Pharma?

Summary

How does Ensysce Biosciences compare to Virios Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENSC vs. The Competition

Ensysce Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ensysce Biosciences (ENSC) Competitors

ENSC vs. CPHI, ABVC, OPTH, LONA, and VIRI

How does Ensysce Biosciences compare to China Pharma?

Do insiders and institutionals have more ownership in CPHI or ENSC?

Does the media refer more to CPHI or ENSC?

Which has stronger earnings and valuation, CPHI or ENSC?

Do analysts rate CPHI or ENSC?

Is CPHI or ENSC more profitable?

Which has more volatility and risk, CPHI or ENSC?

Summary

How does Ensysce Biosciences compare to ABVC BioPharma?

Does the media refer more to ABVC or ENSC?

Do institutionals & insiders believe in ABVC or ENSC?

Do analysts recommend ABVC or ENSC?

Is ABVC or ENSC more profitable?

Which has more volatility and risk, ABVC or ENSC?

Which has preferable valuation & earnings, ABVC or ENSC?

Summary

How does Ensysce Biosciences compare to Optimi Health?

Is OPTH or ENSC more profitable?

Do analysts rate OPTH or ENSC?

Does the media prefer OPTH or ENSC?

Do insiders & institutionals hold more shares of OPTH or ENSC?

Which has stronger valuation & earnings, OPTH or ENSC?

Summary

How does Ensysce Biosciences compare to Athira Pharma?

Which has more volatility and risk, ENSC or LONA?

Does the media refer more to ENSC or LONA?

Do analysts rate ENSC or LONA?

Do institutionals and insiders believe in ENSC or LONA?

Is ENSC or LONA more profitable?

Which has preferable earnings and valuation, ENSC or LONA?

Summary

How does Ensysce Biosciences compare to Virios Therapeutics?

Does the media favor VIRI or ENSC?

Which has more volatility & risk, VIRI or ENSC?

Is VIRI or ENSC more profitable?

Do analysts prefer VIRI or ENSC?

Which has better earnings and valuation, VIRI or ENSC?

Do institutionals & insiders believe in VIRI or ENSC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENSC vs. The Competition

Ensysce Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools